Share on StockTwits

Amarin Co. plc (ADR) (NASDAQ:AMRN) is set to release its Q114 earnings data on Friday, May 9th. Analysts expect Amarin Co. plc (ADR) to post earnings of ($0.18) per share and revenue of $11.65 million for the quarter.

Amarin Co. plc (ADR) (NASDAQ:AMRN) last announced its earnings results on Thursday, February 27th. The company reported ($0.26) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.03. The company had revenue of $10.10 million for the quarter, compared to the consensus estimate of $11.17 million. On average, analysts expect Amarin Co. plc (ADR) to post $-0.61 EPS for the current fiscal year and $-0.32 EPS for the next fiscal year.

Shares of Amarin Co. plc (NASDAQ:AMRN) opened at 1.58 on Thursday. Amarin Co. plc has a one year low of $1.36 and a one year high of $7.98. The stock’s 50-day moving average is $1.71 and its 200-day moving average is $1.8. The company’s market cap is $272.8 million.

A number of research firms have recently commented on AMRN. Analysts at Jefferies Group raised their price target on shares of Amarin Co. plc (ADR) from $3.00 to $3.50 in a research note on Tuesday, April 1st. On the ratings front, analysts at MKM Partners reiterated a “neutral” rating on shares of Amarin Co. plc (ADR) in a research note on Tuesday, April 1st. They now have a $2.00 price target on the stock, up previously from $1.50. Finally, analysts at Aegis reiterated a “hold” rating on shares of Amarin Co. plc (ADR) in a research note on Tuesday, April 1st. Ten research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Amarin Co. plc (ADR) has an average rating of “Hold” and a consensus target price of $4.78.

Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.